Search research articles
Contact Us
Filters
Showing results (291-300 of 320) with videos related to
Page
of 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
Marion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
Günther G Steger, Arik Galid, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases
Allan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid
Miguel Martin, Richard Bell, Hugues Bourgeois, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
Christian F Singer, Yen Y Tan, Florian Fitzal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy
Allan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
R Bell, J Brown, M Parmar, et al.
British Journal of Cancer
|
March 21, 2013
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
G Pfeiler, H Stöger, P Dubsky, et al.
The Lancet. Oncology
|
February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Gnant, Georg Pfeiler, Günther G Steger, et al.
Wiener Klinische Wochenschrift
|
June 16, 2010
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel
Guenther G Steger, Jitka Abrahámová, Florin Bacanu, et al.
Page
of 32
Search research articles
Search
Showing results (291-300 of 320) with videos related to
Sort By:
Page
of 32
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
Marion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14
Günther G Steger, Arik Galid, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases
Allan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid
Miguel Martin, Richard Bell, Hugues Bourgeois, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
Christian F Singer, Yen Y Tan, Florian Fitzal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy
Allan Lipton, Guenther G Steger, Jazmin Figueroa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
R Bell, J Brown, M Parmar, et al.
British Journal of Cancer
|
March 21, 2013
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
G Pfeiler, H Stöger, P Dubsky, et al.
The Lancet. Oncology
|
February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Gnant, Georg Pfeiler, Günther G Steger, et al.
Wiener Klinische Wochenschrift
|
June 16, 2010
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel
Guenther G Steger, Jitka Abrahámová, Florin Bacanu, et al.
Page
of 32